T-cell-based immunotherapies hold promise for the treatment of many types of cancer, with
three approved products for B-cell malignancies and a large pipeline of treatments in clinical …

Vaccines have had a profound impact on the management and prevention of infectious
disease. In addition, the development of vaccines against chronic diseases has attracted …

Oncolytic viruses (OVs) encoding a variety of transgenes have been evaluated as
therapeutic tools to increase the efficacy of chimeric antigen receptor (CAR)–modified T cells …

Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …

Chimeric antigen receptor (CAR)–T cells have shown efficacy in patients with B cell
malignancies. Yet, their application for solid tumors has challenges that include limited …

Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the
body from pathogenic invaders and can be used as tools to enhance the body's defense …

In recent decades, the advent of immune-based therapies, most notably Chimeric antigen
receptor (CAR)-T cell therapy has revolutionized cancer treatment. The promising results of …

Chimeric antigen receptor–T cell (CAR-T) therapy has been effective in the treatment of
hematologic malignancies, but it has shown limited efficacy against solid tumors. Here we …

T cells engineered to express chimeric antigen receptors (CARs) that are specific for tumour
antigens have led to high complete response rates in patients with haematologic …

Although cancer immunotherapy has taken center stage in mainstream oncology inducing
complete and long-lasting tumor regression, only a subset of patients receiving treatment …